Literature DB >> 2738608

Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone.

Y Ihara1, R Namba, S Kuroda, T Sato, T Shirabe.   

Abstract

Two patients with mitochondrial myopathy, encephalopathy, lactic acidosis and strokelike episodes (MELAS) in one family are reported. Pathological examination of case 1 showed ragged-red fibers, with 7% of the fibers being unstained by cytochrome c oxidase stain, peripheral nerve damage, multiple areas of softening in the cerebrum and midbrain, and spongy changes in the cerebrum, optic nerve and pons. Electron microscopic examination revealed abnormal accumulations of mitochondria in the skeletal muscle, smooth muscle and cardiac muscle. The activity of cytochrome c oxidase in the brain and liver showed a tendency to decrease. In case 2 (maternal aunt of case 1), muscular weakness and peripheral nerve damage improved by treatment with coenzyme Q10. By adding idebenone to the coenzyme Q10 therapy, the EEG and Wechsler's Adult Intelligence Scale (WAIS) improved. Furthermore, in the cerebral spinal fluid (CSF), the protein, lactate, and pyruvate decreased, and the monoamines and monoamine metabolites increased.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2738608     DOI: 10.1016/0022-510x(89)90112-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  28 in total

1.  Melas syndrome.

Authors:  S K Singh; D Sarin; J M Puliyel; R Srivastav; R Gupta; N Kumar; A Mathews
Journal:  Indian J Pediatr       Date:  1999 Jul-Aug       Impact factor: 1.967

2.  Mitochondrial genome: defects, disease, and evolution.

Authors:  A Clarke
Journal:  J Med Genet       Date:  1990-07       Impact factor: 6.318

3.  Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects.

Authors:  R T Matthews; L Yang; S Browne; M Baik; M F Beal
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

4.  Could coenzyme Q10 and L-carnitine be a treatment for diabetes secondary to 3243 mutation of mtDNA?

Authors:  P Silvestre-Aillaud; D BenDahan; V Paquis-Fluckinger; J Pouget; J F Pelissier; C Desnuelle; P J Cozzone; B Vialettes
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

Review 5.  Primary lipid cardiomyopathy.

Authors:  A Zimmermann; P Wyss; F Stocker
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

Review 6.  The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options.

Authors:  Fernando Scaglia; Jennifer L Northrop
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

7.  Maternally inherited deafness and unusual phenotypic manifestations associated with A3243G mitochondrial DNA mutation.

Authors:  Katalin Komlósi; Richárd Kellermayer; Anita Maász; Viktória Havasi; Katalin Hollódy; Olga Vincze; Hajnalka Merkli; Endre Pál; Béla Melegh
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

8.  Metabolic interventions against complex I deficiency in MELAS syndrome.

Authors:  K Majamaa; H Rusanen; A Remes; I E Hassinen
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

9.  Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.

Authors:  Marianna Sikorska; Patricia Lanthier; Harvey Miller; Melissa Beyers; Caroline Sodja; Bogdan Zurakowski; Sandhya Gangaraju; Siyaram Pandey; Jagdeep K Sandhu
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

10.  Pearson bone marrow-pancreas syndrome with insulin-dependent diabetes, progressive renal tubulopathy, organic aciduria and elevated fetal haemoglobin caused by deletion and duplication of mitochondrial DNA.

Authors:  A Superti-Furga; E Schoenle; P Tuchschmid; R Caduff; V Sabato; D DeMattia; R Gitzelmann; B Steinmann
Journal:  Eur J Pediatr       Date:  1993-01       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.